Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neovascularization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    171 result(s) found for: Neovascularization. Displaying page 2 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2014-003661-18 Sponsor Protocol Number: 2014-878 Start Date*: 2015-09-29
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Phase II study evaluating the efficacy of aflibercept for the treatment of choroidal neovascularization complicating angioid streaks in young subjects: the ASTRID study
    Medical condition: choroidal neovascularization complicating angioid streaks
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10060823 Choroidal neovascularisation PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002431-15 Sponsor Protocol Number: CRFB002ADE23 Start Date*: 2013-10-09
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 12-month, phase IV, randomized, open label, multicenter study to compare efficacy of 0.5 mg ranibizumab PRN compared to 2 mg aflibercept bimonthly intravitreal injections on retinal thickness sta...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) NO (Completed) AT (Completed) DK (Completed) BE (Completed) NL (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003210-10 Sponsor Protocol Number: B0451001 Start Date*: 2009-09-24
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: PHASE II OPEN LABEL, MULTICENTER, PROSPECTIVE,RELATED MACULAR DEGENERATION, COMPARATOR STUDY EVALUATING PF-04523655 VERSUS RANIBIZUMAB TREATMENT OF SUBJECTS WITH CHOROIDAL NEOVASCULARIZATION (MONET...
    Medical condition: Subfoveal Choroidal Neovascularization (CNV) associated with Age-related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) BE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-002626-23 Sponsor Protocol Number: CRFB002A2411 Start Date*: 2013-11-26
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A 12-month, phase IIIb, randomized, visual acuity, assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen,...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) BE (Completed) DE (Completed) SK (Completed) GB (Completed) HU (Completed) PT (Completed) DK (Completed) SI (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003640-23 Sponsor Protocol Number: ECR-RET-2013-05 Start Date*: 2014-01-13
    Sponsor Name:AIBILI - Association for Innovation and Biomedical Research on Light and Image
    Full Title: Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP ...
    Medical condition: Patients with type I or type II diabetes mellitus and high risk diabetic retinopathy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10036857 Proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006785-15 Sponsor Protocol Number: IOBA-02-2007 Start Date*: 2008-03-10
    Sponsor Name:IOBA - Instituto Universitario de Oftalmobiología Aplicada
    Full Title: EFFICACY AND SECURITY OF INTRAVITREAL BEVACIZUMAB IN THE TREATMENT OF CHOROIDAL NEOVASCULAR MEMBRANES ASSOCIATED TO HIGH MYOPIA EVALUACIÓN DE LA EFICACIA Y SEGURIDAD DE LA INYECCIÓN INTRAVÍTREA D...
    Medical condition: Choroidal neovascular membrane in high myopia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060823 Choroidal neovascularisation LLT
    9.1 10051455 Malignant myopia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001182-27 Sponsor Protocol Number: CRFB002ADE27 Start Date*: 2014-08-27
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until stu...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000743-95 Sponsor Protocol Number: CRFB002A2402 Start Date*: 2007-08-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-...
    Medical condition: Study population will consist of patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who received treatment in either of the two ongoing ranibizumab...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) NL (Completed) DE (Completed) PT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003695-23 Sponsor Protocol Number: 69HCL14-0201 Start Date*: 2015-07-21
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Phase II study evaluating the efficacy of aflibercept for the treatment of inflammatory choroidal neovascularization in young subjects: the ALINEA study
    Medical condition: inflammatory choroidal neovascularization
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005601-22 Sponsor Protocol Number: poc1doxy Start Date*: 2008-03-27
    Sponsor Name:
    Full Title: Proof–of–concept study 1 (POC1): Evaluation of effect of doxycycline versus placebo on retinal function and posterior segment neovascularization in patients with severe non-proliferative or early ...
    Medical condition: Diabetic retinopathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012689 Diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004844-35 Sponsor Protocol Number: TG-MV-005 Start Date*: 2009-07-01
    Sponsor Name:ThromboGenics NV
    Full Title: A randomized, sham-injection controlled, double-masked, multicenter trial of microplasmin intravitreal injection for treatment of exudative age-related macular degeneration (AMD).
    Medical condition: Patients with exudative AMD with focal vitreomacular adhesion
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015902 Exudative senile macular degeneration of retina LLT
    9.1 10051065 Vitreomacular traction syndrome LLT
    9.1 10060823 Choroidal neovascularisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004416-31 Sponsor Protocol Number: 206207-016 Start Date*: 2008-03-07
    Sponsor Name:Allergan Limited
    Full Title: A 6-Month, Single-Masked, Multicenter, Randomized, Controlled Study to Assess the Safety and Efficacy of 700 μg Dexamethasone Posterior Segment Drug Delivery System Applicator System as Adjunctive ...
    Medical condition: Choroidal neovascularization secondary to age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) GB (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002384-15 Sponsor Protocol Number: 3.0 Start Date*: 2014-10-23
    Sponsor Name:Universitätsklinik für Augenheilkunde und Optometrie
    Full Title: Intravitreal Aflibercept treatment in RAP-Lesions, PED, hemorrhagic CNV and PCV
    Medical condition: Exsudative Maculopathies
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10063381 Polypoidal choroidal vasculopathy PT
    17.0 10015919 - Eye disorders 10052501 Detachment of retinal pigment epithelium PT
    17.0 10015919 - Eye disorders 10069125 Retinal angiomatous proliferation LLT
    17.0 10015919 - Eye disorders 10060823 Choroidal neovascularisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012941-45 Sponsor Protocol Number: CRVO_LUC_09 Start Date*: 2009-10-26
    Sponsor Name:Glostrup Hospital
    Full Title: LuRVO: Classification of Central Retinal Vein Occlusion and Management with Lucentis (Ranibizumab) - a randomised clinical trial.
    Medical condition: Central nethindeveneokklusion (e. central retinal vein occlusion, CRVO)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007972 Central retinal vein occlusion LLT
    9.1 10054467 Macular edema LLT
    9.1 10029114 Neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001085-10 Sponsor Protocol Number: CRFB002AGB17 Start Date*: 2014-09-08
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: A phase IV, prospective, open label, uncontrolled, European study in patients with neovascular age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching from intravit...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001856-36 Sponsor Protocol Number: MEDICARE Start Date*: 2013-08-05
    Sponsor Name:CHU DE POITIERS
    Full Title: Efficacy and safety of Aflibercept (Eylea®) in proliferative diabetic retinopathy
    Medical condition: Percentage of patients showing regression of retinal neovascularization between baseline and month 12 in the Aflibercept group versus laser group
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10036857 Proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021662-30 Sponsor Protocol Number: CRFB002F2301 Start Date*: 2010-11-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12 month, phase III, randomized, double-masked, multi-center, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs. verteporfin PD...
    Medical condition: visual impairment due to choroidal neovascularization secondary to pathologic myopia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036803 Progressive high (degenerative) myopia LLT
    12.1 10060837 Choroidal neovascularization LLT
    12.1 10047571 Visual impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) LV (Completed) HU (Completed) LT (Completed) FR (Completed) ES (Completed) IT (Completed) AT (Completed) SK (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005388-33 Sponsor Protocol Number: GS101-P3-CG Start Date*: 2009-02-03
    Sponsor Name:Les Laboratoires CTRS
    Full Title: A MULTICENTRE DOUBLE-BLIND RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF GS-101 EYE DROPS, AN ANTISENSE OLIGONUCLEOTIDE, VERSUS PLACEBO ON INHIBITION OF CORNEAL NEOVASCULARIZATIO...
    Medical condition: Patients with corneal neovascularization, a major risk factor of corneal graft rejection.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2013-001421-55 Sponsor Protocol Number: CRFB002GFR02 Start Date*: 2013-06-13
    Sponsor Name:Novartis Pharma S.A.S
    Full Title: An open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases.
    Medical condition: Choroidal neovascularization not related to wet Age-related macular degeneration (wAMD), pathologic myopia (PM)or Pseudoxanthoma elasticum (PXE), as well as in Macular Edema (ME) not related to Ret...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10047060 Retina, choroid and vitreous haemorrhages and vascular disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-004867-31 Sponsor Protocol Number: EOP 1012D Start Date*: 2005-04-12
    Sponsor Name:(OSI) Eyetech Pharmaceuticals, Inc
    Full Title: A Phase 3B/4, randomized, active controlled, double-masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of Macug...
    Medical condition: Exudative Age Related Macular Degeneration (AMD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Prematurely Ended) AT (Completed) DE (Prematurely Ended) IT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 09 18:56:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA